Spingolipids in multiple sclerosis

Cellular Physiology and Biochemistry

Volumn 26, Issue 1, 2010, Pages 49-56

  Walter, Silke ^a   Faßbender, Klaus ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Ceramide; Gangliosides; Multiple Sclerosis; Phingosine 1 phosphate; Sphingolipids; Sphingomyelin; Sphingomyelinase; Sphingosine

Indexed keywords

FINGOLIMOD; GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; GANGLIOSIDE GM1; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADRENOLEUKODYSTROPHY; ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; HUMAN; HYPOXIA; INFLAMMATORY INFILTRATE; LIPID METABOLISM; LYMPHOCYTE MIGRATION; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 77952900059     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315105     Document Type: Review

References (69)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
2. Tomassini V, Palace J. Multiple sclerosis lesions: insights from imaging techniques. Expert Rev Neurother 2009;9:1341-1359
3. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005;252 Suppl 5:v3-9.
4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. N Engl J Med 2000;343:938-952.
5. Bitsch A, Brueck W. Differentiation of multiple sclerosis subtypes: implications for treatment.CNS Drugs 2002;16:405-418.
6. Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 2000,23:317-327.
7. Frohman EM, Racke MK, Raine CS. Medical Progress: Multiple Sclerosis-The Plaque and Its Pathogenesis. The New England J.Med 2006;354:942-955.
8. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clin. Pract. Neurol 2006;2:201-211.
9. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994;36 Suppl:S47-S53.
10. Petry KG, Boullerne AI, Pousset F, Brochet B, Caille JM, Dousset V. Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis. Pathol Biol 2000;48:47-53.
11. Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 2006;84:532-543.
12. Steinman L. Multiple sclerosis: a coordinated immunological attack against my-elin in the central nervous system. Cell 1996;85:299-302.
13. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005;26:485-495.
14. Kniesel U, Wolburg H. Tight junctions of the blood-brain-barrier. Cell. Mol. Neurobiol 2000;20:57-76.
15. Kerfoot S, Kubes P. Overlapping roles of P-selectin and a4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune en-cephalomyelitis, J Immunol 2002; 169: 1000-1006.
16. Alt C, Laschinger M, Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-depend-ent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 2002;32:2133-2144.
17. Columba-Cabezas S, Serafini B, Ambosini E, Aloisi F. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol 2003;13:38-51.
18. Piccio L, Rossi B, Scarpini E, Laudanna C, Giagulli C, Issekutz AC, Vestweber D, Butcher EC, Constantin G. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol 2002;168:1940-1949.
19. Laschinger M, Vajkoczy P, Engelhardt B. Encephalitogenic T cells use LFA-1 for transendothelial migration but not during capture and initial adhesion strengthening in healthy spinal cord microvessels in vivo. Eur J Immunol 2002;32:3598-3606.
20. Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, Ottoboni L, Ciabini D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003;101:4775-4782.
21. Engelhardt B, Wolburg H. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol 2004;34:2955-2963.
22. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005;11:328-334.
23. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96:2195-2203.
24. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999;162:1818-1826.
25. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, Sorokin LM. Dystroleglycan is selectively cleaved ast the parenchymal basement at sites of leukocyte extravasation in experimental autoimmune encepha-lomyelitis. J Exp Med 2006;203:1007-1019.
26. Frohman EM, Filipppi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Ann Neurol 2006;62:1345-1356.
27. Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggings JN, Harrington MG. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers 2006;22:39-64.
28. Yousseff S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvill SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
29. Neuhaus O, Stuve O, Zamvill SS, Hartung H P. Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004;3:369-371 (Pubitemid 38648858)
30. Ifergan I, Wosik K, Cayrol R, Kebir H, Auger C, Bernard M, Bouthhillier A, Moumdjian R, Duquette P, Prat A. Statins reduce human blood-brain barrier permeability and restricts leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006;60:45-55.
31. Farooqui AA. Lipid Mediators in the Neural Cell Nucleus: Their Metbolism, Signaling, and Association with Neurological Disorders. The Neuroscientist, Volume 15 Number, 4 August 2009 392-407.
32. Hicks AA, Pramstaller PP, Johansson A, Vitart V, Rudan I, Ugocsai P, Aulchenko Y, Franklin CS, Liebisch G, Erdmann J, Jonasson I, Zorkoltseva I V, Pattaro C, Hayward C, Isaacs A, Hengstenberg C, Campbell S, Gnewuch C, Janssens AC, Kirichenko AV, König IR, Marroni F, Polasek O, Demirkan A, Kolcic I, Schwienbacher C, Igl W, Biloglav Z, Witteman JC, Pichler I, Zaboli G, Axenovich TI, Peters A, Schreiber S, Wichmann HE, Schunkert H, Hastie N, Oostra BA, Wild SH, Meitinger T, Gyllenstein U, van Duijn CM, Wilson JF, Wright A, Schmitz G, Campbell H. Genetic determinants of circulation sphin-golipid concentrations in European populations. PLoS Genet 2009;5:e1000672.
33. Clement AB, Gamerdinger M, Tamboli I Y, Lütjohann D, Walter J, Greeve I, Gimpl G, Behl C. Adaptation of neuronal cells to chronic oxidative stress is associated with altered cholesterol and sphin-golipid homeostasis and lysosomal function. Neurochem. 2009;111:669-682.
34. Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, Singh I. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 2003;14:425-439
35. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12:138-143
36. Huwiler A, Johansen B, Skarstad AM, Pfeilschifter J. Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J 2001;15:7-9.
37. Muller G, Ayoub B, Storz P, Rennecke J, Fabbro D, Pfizenmaier K. PCKζ is a molecular switch in signal transduction of TNF-α, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 1995;14:1961-1969.
38. Zhang Y, Yao B, Delikat S, Bayoumi S, Lin XH, Basu S, McGinley M, Chan-Hui P Y, Lichenstein H, Kolenick R. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997;89:63-72.
39. Dobrowski RT, Hannun YA. Ceramide-activated protein phosphatase partial purification and relationship to protein phosphatase 2A. Adv Lipid Res 1993;25:91-94.
40. Kolesnick R, Xing HR. Inflammatory bowel disease reveals the kinase activity of KSR1. J Clin Invest 2004;114:1272-1280.
41. O'Keeffe J, Gately CM, Counihan T, Hennessy M, Leahy T, Moran AP, Hogan EL. T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired. J. Neurol Sci 2008;275:22-28
42. Saadat L, Dupree JL, Kilkus J, Han X, Traka M, Proia RL, Dawson G, Popko B. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice. Glia 2010;58:391-398.
43. Prasad VV, Nithipatikom K, Harder DR. Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes. Neurochem Int 2008;53:220-229
44. Goris A, Sawcer S, Vanderbroeck K, Carton H, Billiau A, Setakis E, Compston A, Dubois B. New canididate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population. J Neuroimmunol 2003;143:65-69
45. Jana A, Pahan K. Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: Implications for multiple sclerosis. J Neuroimmune Pharmacol 2007;2:184-193.
46. Crivello NA, Rosenberg IH, Dallal GE, Bielinski, D. Joseph JA. Age-related changes in neutral sphingomyelin-spe-cific phospholipase C activity in stria-tum, hippocampus, and frontal cortex: implication for sensitivity to stress and inflammation. Neurochem Int 2005;47:573-579
47. Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trend Cell Bio 2005;15:312-318.
48. Bollinger CR, Teichgräber V, Gulbins E.Ceramide-enriched membrane domains. Biochimica et Biophysica Acta 2005;1746:284-294.
49. Gulbins E, Li PL. Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 2006;290:R11-R26.
50. Schneider-Brachert W, Tchikov V, Neumayer J, Jacob M, Winoto-Morbach S, Held-Feindt J, Heinrich M, Merkel O, Ehrenschwender M, Adam D, Mentlein R, Kabelitz D, Schutze S. Compartmentalization of TNF receptor 1 signaling. Internalized TNF receptosomes as death vesicles. Immunity 2004;21:415-428.
51. Garcia-Barros M, Lacorazza D, Petrie H, Haimovitz-Friedman A, Cardon-Cardo C, Nier S, Fuks Z, Kolesnick R. Host acid sphingomyelinase regulates microvascu-lar function not tumor immunity. Cancer Res 2004;64:8285-8291.
52. Boucher LM, Wiegmann K, Futterer A, Pfeffer K, Machleidt T, Schutze S, Mak TW, Krönke M. CD28 signals through acidic sphingomyelinase. J Exp Med 2005;181:2059-2068.
53. Stoffel B, Bauer P, Nix M, Geres K, Stoffel W. Ceramide-independent CD28 and TCR signaling but reduced IL-2 secretion in T cells of acid sphingomyelinase-deficient mice. Eur J Immunol 1998;28:874-880.
54. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnock R, Gulbins E. CD95 signaling via ceramide-rich membrane rafts mediate CD40 clustering. J Immunol 2002;168:298-307.
55. Phong MC, Gutwein P, Kadel S, Hexel K, Altevogt P, Linderkamp O, Brenner B. Molecular mechanisms of L-selectin-in-duced co-localization in rafts and shedding. Biochem Biophys Res Commun 2003;300:563-569.
56. Rosenman SJ, Ganji AA, Tedder TF, Gallatin WM. Syn-capping of human T lymphocyte adhesion/activation molecules and their resitrubution during interaction with endothelial cells. J Leukoc Biol 1993;53:1-10.
57. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008 Jan 24;51:219-237
58. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, DJ Heersema, van Buchem MA, De Keyser J. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol. Neurosurg. Psychiatry published online 1 May 2008. doi:10.1136/jnnp.2007.139345.
59. Spiegel S, Milstien S. Sphingosine-1-phos-phate: an enigmatic signalling lipid. Nature Rev Mol Cell Biol 2003;4:397-407.
60. Chalfant EC, Spiegel S. Spingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signalling. J Cell Science 2005;118:4605-4612.
61. Rosen H, Goetzl EJ. Sphingosine 1-phos-phate and its receptors: an autocrine and paracrine network. Nature Rev Immunol 2005;5:560-570.
62. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine1-phosphate receptors in mouse splenic T cells. FASEB J 2002;16:1874-1878.
63. Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest 2004;114:1531-1537.
64. Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine 1 phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 2005;201:291-301.
65. Weigert A, Weis N, Brüne B. Regulation of macrophage function by sphingosine-1-phosphate. Immunbiology 2009;214:748-760
66. Monteiro de Castro G, Eduarda Zanin M, Ventura-Oliveira D, Aparecida Vilella C, Ashimine R, de Lima Zollner R. Th1 and Th2 cytokine immunomodulation by gangliosides in experimental autoimmune encephalomyelitis. Cytokine 2004;26:155-163
67. Marconi S, De Toni L, Lovato L, Tedeschi E, Gaetti L, Acler M, Bonetti B. Expression of gangliosides on glial and neuronal cells in normal and pathological adult human brain. J Neuroimmunol 2005;170:115-121
68. Marconi S, Acler M, Lovato L, De Toni L, Tedeschi E, Anghileri E, Romito S, Cordioli C, Bonetti B. Anti-GD2-like lgM autoreactivity in multiple sclerosis patients. Mult Scler 2006;12:302-308
69. Kanda T, Ariga T, Kubodera H, Jin HL, Owada K, Kasama T, Yamawaki M, Mizusawa H. Glycosphingolipid composition of primary cultured human brain microvascular endothelial cells. J Neurosci Res 2004;78:141-150